Mutations in MT-ND1, MT-ND2, MT-ND4, and MT-ND5, crucial for Complex I function, lead to altered bioenergetics and increased oxidative stress, contributing to GBM’s aggressiveness and therapeutic resistance (Viale et al., 2015). This evidence concerns the gene MT-ND2 and glioblastoma.